NW Kentucky News

WASHINGTON—House Committee on Oversight and Accountability Chairman James Comer (R-Ky.) criticized the U.S. Food and Drug Administration (FDA) for its shortcomings in prioritizing safety and fostering innovation during a hearing titled “Oversight of the U.S. Food and Drug Administration.”

In his opening remarks, Comer emphasized the importance of the FDA's role in regulating the food and drug industries, stating, "There might not be a federal agency that is more integral to Americans’ day-to-day lives than the FDA." He highlighted the necessity for Congress to ensure that the FDA is focusing on safety, effectiveness, and innovation.

Comer expressed concern over the FDA's performance under President Biden, noting that the agency is facing dysfunction and failing to fulfill its fundamental mission of ensuring the safety and efficacy of food and drug products. He pointed out specific instances where the FDA's lack of preparedness had severe consequences, such as the infant formula crisis, which resulted in shortages and left families struggling to access essential products.

The Chairman also raised issues regarding drug shortages, off-shoring of pharmaceutical manufacturing, and the FDA's failure to regulate tobacco and hemp-derived products effectively. Comer criticized the FDA for neglecting its regulatory responsibilities, leading to confusion in the market and potential risks for consumers.

"These examples are just scratching the surface of the dysfunction and failures that are ongoing within the FDA," Comer stated, underscoring the need for a thorough examination of the FDA's actions to ensure a safe food and drug supply.

The hearing aimed to shed light on the challenges facing the FDA and explore ways to address the issues identified by the Committee. Comer's remarks set the tone for a critical evaluation of the FDA's performance and its impact on public health and safety.